MBX Biosciences, Inc.

Today, on #WorldHypoparathyroidismDay, we stand with the estimated 250,000+ people worldwide living with #hypoparathyroidism (HP). At MBX Biosciences, we recognize the significance of today and the profound impact HP has on individuals and communities worldwide. Through our ongoing efforts with the HypoPARAthyroidism Association, we strive to raise awareness, drive meaningful change and create a more inclusive and compassionate community for these individuals. Join us today and every day as we stand with HP patients worldwide. Together, we can make a difference.

The STEM Connection is an amazing non-profit in northern Indianapolis that connects children from diverse backgrounds to STEM educational activities. Last week, MBX Biosciences gathered our growing team from across the country for a Together Week at our home office in Carmel, IN. Together Weeks allow MBXers to connect with each other, the patient community we hope to serve and the local community. We are so happy to have spent time with The STEM Connection, as we value their mission and the work they do. We hope to one day employ STEM professionals whose passions were ignited by the efforts of The STEM Connection.

#ICYMI Our Scientific Co-Founder, Richard DiMarchi, Ph.D., was recently awarded the Mani L. Bhaumik 2023 Breakthrough of the Year Award from the AAAS! Dr. DiMarchi is a world class innovator, inventor and one of the world’s leading peptide chemists who helped lay the foundation for the development of new classes of therapeutic agents that effectively treat #obesity and reduce the risk of #diabetes. Thanks to the pioneering work of Dr. DiMarchi, patients have a range of treatment options to help better manage their conditions and improve their quality of life. Join us in congratulating Dr. DiMarchi for this well-deserved recognition!  Missed the ceremony? Watch a replay here: https://lnkd.in/eghP7nCB 

We are thrilled that our Scientific Co-Founder, Richard DiMarchi, Ph.D., will receive the prestigious 2023 Mani L. Bhaumik Breakthrough of the Year Award presented by the American Association for the Advancement of Science (AAAS)! His leadership and groundbreaking research have played an indispensable role in the discovery of the GLP-1/GIP dual agonist, a revolutionary treatment for #obesity and #diabetes.    As developer of the original Precision Endocrine Peptide (PEP) technology, Dr. DiMarchi’s contributions are foundational in our efforts to develop precision peptide therapies for people with endocrine and metabolic disorders.    We congratulate Dr. DiMarchi on this recognition that underscores his relentless pursuit of scientific innovation and commitment to the broader scientific community!   Register for the event on April 26 or learn more: https://lnkd.in/eghP7nCB     Tune in to the award ceremony: https://lnkd.in/eriq5-mi 

Current #hypoparathyroidism treatments require frequent dosing, which can be both inconvenient, and result in wide fluctuations in the bloodstream, potentially impacting efficacy and side effects of the medicine. At MBX Biosciences, patients are at the forefront of our approach to developing new and better medicines to manage hypoparathyroidism (HP).     Learn more about how MBX-2109, our investigational long-acting parathyroid hormone (PTH) peptide prodrug, aims to deliver consistent therapeutic benefits while minimizing disruptions to daily life through a once-weekly dosing regimen.    #biotechnology

At MBX, we strive to cultivate a collaborative community where each member of our team plays an integral role in our journey to reshape the treatment landscape for those living with #endocrine disorders.   Join us in transforming the future of medicine and science: https://lnkd.in/eeMrdY5e   #biotechnology #careers

This week, MBX was proud to help support the Externally-Led Patient-Focused Drug Development Meeting hosted by the HypoPARAthyroidism Association. At MBX, we believe collaboration is key and events like these provide a vital platform for patients, caregivers, and experts to come together. We are committed to addressing the unmet medical needs faced by patients with #hypoparathyroidism, and to pioneering the next generation of medicines to improve quality of life for these individuals. #HP 

This week, MBX was proud to help support the Externally-Led Patient-Focused Drug Development Meeting hosted by the HypoPARAthyroidism Association. At MBX, we believe collaboration is key and events like these provide a vital platform for patients, caregivers, and experts to come together. We are committed to addressing the unmet medical needs faced by patients with #hypoparathyroidism, and to pioneering the next generation of medicines to improve quality of life for these individuals. #HP 

As we observe #RareDiseaseDay, MBX is honored to stand with the global community to shine a light on the challenges faced by over 300 million people living with #rarediseases, many of which are serious and rare endocrine disorders. Every day, we strive to advance new treatment options for patients living with these diseases. From our office in Carmel, Indiana to our growing lab space in Indianapolis and other remote hybrid/remote locations, here are some of our incredible team members wearing stripes in honor of Rare Disease Day:   #showyourstripes

Rare Disease Day is approaching, and at MBX, we are committed to raising awareness and developing new treatment options for patients living with these diseases, including #hypoparathyroidism (HP). Over 100,000 individuals in the U.S. have #HP, yet the current standard of care does not target the underlying pathophysiology of the disease. Our CSO, Steve Prestrelski, Ph.D., shares how our pipeline of precision endocrine peptides (PEPs)™ strive to meet the of needs people faced with rare endocrine disorders. Learn more: https://lnkd.in/eqp68Nze   #RareDiseaseDay